UK MHRA Scientific Advice on Pivotal Trial of NG13-2, a Novel Product for the Prevention of Chemotherapy-Induced Alopecia
11th -July- 2025
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the company has received the notification of the Date for Scientific Advisory meeting from the MHRA on the NG13-2 programme for the prevention of chemotherapy-induced alopecia. The meeting date is assigned for early September, aiming to seek advice on the pivotal Phase 2b/3 trial design and market approval approaches for NG13-2, a novel product for the prevention of chemotherapy-induced alopecia.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
"We are pleased to receive the confirmation of the Scientific Advisory meeting date from MHRA. We greatly appreciate the opportunity to discuss and obtain advice on the protocol design for the NG13-2 pivotal trial and the approaches for market approval in UK and beyond. This is a stepping stone for us to clarify the roadmap to bring NG 13-2 to the patients-in-need and the market in the UK and worldwide."
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company's proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.